These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1231 related articles for article (PubMed ID: 30144434)

  • 1. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.
    Kanwal F; Kramer JR; Mapakshi S; Natarajan Y; Chayanupatkul M; Richardson PA; Li L; Desiderio R; Thrift AP; Asch SM; Chu J; El-Serag HB
    Gastroenterology; 2018 Dec; 155(6):1828-1837.e2. PubMed ID: 30144434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
    Simon TG; Roelstraete B; Sharma R; Khalili H; Hagström H; Ludvigsson JF
    Hepatology; 2021 Nov; 74(5):2410-2423. PubMed ID: 33811766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
    Ioannou GN; Green P; Kerr KF; Berry K
    J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes.
    Natarajan Y; Kramer JR; Yu X; Li L; Thrift AP; El-Serag HB; Kanwal F
    Hepatology; 2020 Oct; 72(4):1242-1252. PubMed ID: 32022277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study.
    Huang DQ; Tran S; Barnett S; Zou B; Yeo YH; Cheung R; Nguyen MH
    Hepatol Int; 2024 Apr; 18(2):540-549. PubMed ID: 38079023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis.
    Behari J; Gougol A; Wang R; Luu HN; Paragomi P; Yu YC; Molinari M; Chopra K; Malik SM; Geller D; Yuan JM
    Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37395730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013.
    Beste LA; Leipertz SL; Green PK; Dominitz JA; Ross D; Ioannou GN
    Gastroenterology; 2015 Nov; 149(6):1471-1482.e5; quiz e17-8. PubMed ID: 26255044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
    Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
    BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Chan TT; Chan WK; Wong GL; Chan AW; Nik Mustapha NR; Chan SL; Chong CC; Mahadeva S; Shu SS; Lai PB; Chan HL; Wong VW
    Am J Gastroenterol; 2020 Jun; 115(6):867-875. PubMed ID: 32149781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.
    Pais R; Fartoux L; Goumard C; Scatton O; Wendum D; Rosmorduc O; Ratziu V
    Aliment Pharmacol Ther; 2017 Nov; 46(9):856-863. PubMed ID: 28857208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease.
    Kanwal F; Kramer JR; Li L; Dai J; Natarajan Y; Yu X; Asch SM; El-Serag HB
    Hepatology; 2020 Mar; 71(3):808-819. PubMed ID: 31675427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population.
    Kogiso T; Sagawa T; Kodama K; Taniai M; Hashimoto E; Tokushige K
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1579-1589. PubMed ID: 31975453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should Patients With NAFLD/NASH Be Surveyed for HCC?
    Reig M; Gambato M; Man NK; Roberts JP; Victor D; Orci LA; Toso C
    Transplantation; 2019 Jan; 103(1):39-44. PubMed ID: 30080818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A risk prediction model for hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis: HCC prediction for non-cirrhotic NAFLD.
    Kim GA; Park Y; Oh SJ; Jung J; Han S; Chang HS; Park SW; Kim TH; Park HW; Choe J; Kim J; Lee HC
    Liver Int; 2024 Mar; 44(3):738-748. PubMed ID: 38110797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD.
    Önnerhag K; Nilsson PM; Lindgren S
    Scand J Gastroenterol; 2014 Sep; 49(9):1111-8. PubMed ID: 24990583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease.
    Lee TY; Wu JC; Yu SH; Lin JT; Wu MS; Wu CY
    Int J Cancer; 2017 Oct; 141(7):1307-1314. PubMed ID: 28509327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population.
    Mittal S; Sada YH; El-Serag HB; Kanwal F; Duan Z; Temple S; May SB; Kramer JR; Richardson PA; Davila JA
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):594-601.e1. PubMed ID: 25148760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.
    Tokushige K; Hashimoto E; Kodama K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():88-92. PubMed ID: 24251711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
    Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
    Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.